Influenza A H5N1 Clade 2.3.4 Virus with a Different Antiviral Susceptibility Profile Replaced Clade 1 Virus in Humans in Northern Vietnam

Abstract

Background

Prior to 2007, highly pathogenic avian influenza (HPAI) H5N1 viruses isolated from poultry and humans in Vietnam were consistently reported to be clade 1 viruses, susceptible to oseltamivir but resistant to amantadine. Here we describe the re-emergence of human HPAI H5N1 virus infections in Vietnam in 2007 and the characteristics of the isolated viruses.

Methods and Findings

Respiratory specimens from patients suspected to be infected with avian influenza in 2007 were screened by influenza and H5 subtype specific polymerase chain reaction. Isolated H5N1 strains were further characterized by genome sequencing and drug susceptibility testing. Eleven poultry outbreak isolates from 2007 were included in the sequence analysis. Eight patients, all of them from northern Vietnam, were diagnosed with H5N1 in 2007 and five of them died. Phylogenetic analysis of H5N1 viruses isolated from humans and poultry in 2007 showed that clade 2.3.4 H5N1 viruses replaced clade 1 viruses in northern Vietnam. Four human H5N1 strains had eight-fold reduced in-vitro susceptibility to oseltamivir as compared to clade 1 viruses. In two poultry isolates the I117V mutation was found in the neuraminidase gene, which is associated with reduced susceptibility to oseltamivir. No mutations in the M2 gene conferring amantadine resistance were found.

Conclusion

In 2007, H5N1 clade 2.3.4 viruses replaced clade 1 viruses in northern Vietnam and were susceptible to amantadine but showed reduced susceptibility to oseltamivir. Combination antiviral therapy with oseltamivir and amantadine for human cases in Vietnam is recommended.

About the Authors:

Mai T. Q. Le

Affiliation: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Heiman F. L. Wertheim

* E-mail: [email protected]

Affiliations Oxford University Clinical Research Unit, Hanoi, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Hien D. Nguyen

Affiliation: National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

Walter Taylor

Affiliations Oxford University Clinical Research Unit, Hanoi, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Phuong V. M. Hoang

Affiliation: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Cuong D. Vuong

Affiliation: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Hang L. K. Nguyen

Affiliation: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Ha H. Nguyen

Affiliation: National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

Thai Q. Nguyen

Affiliation: National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

Trung V. Nguyen

Affiliation: National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

Trang D. Van

Affiliation: National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

Bich T. Ngoc

Affiliation: Oxford University Clinical Research Unit, Hanoi, Vietnam

Thinh N. Bui

Affiliation: Bach Mai Hospital, Hanoi, Vietnam

Binh G. Nguyen

Affiliation: Bach Mai Hospital, Hanoi, Vietnam

Liem T. Nguyen

Affiliation: National Hospital of Pediatrics, Hanoi, Vietnam

San T. Luong

Affiliation: National Hospital of Pediatrics, Hanoi, Vietnam

Phuc H. Phan

Affiliation: National Hospital of Pediatrics, Hanoi, Vietnam

Hung V. Pham

Affiliation: National Hospital of Pediatrics, Hanoi, Vietnam

Tung Nguyen

Affiliation: National Center for Veterinary Diagnosis, Hanoi, Vietnam

Annette Fox

Affiliations Oxford University Clinical Research Unit, Hanoi, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Cam V. Nguyen

Affiliation: National Center for Veterinary Diagnosis, Hanoi, Vietnam

Ha Q. Do

Affiliations Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Martin Crusat

Affiliations Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Jeremy Farrar

Affiliations Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Hien T. Nguyen

Affiliation: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Menno D. de Jong

Affiliations Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Peter Horby

Affiliations Oxford University Clinical Research Unit, Hanoi, Vietnam, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Introduction

The host specificity of avian influenza A (H5N1) viruses is generally restricted to birds but occasionally these viruses cross the species barrier to infect mammals, including humans [1]. Since 2003, a total of 373 human infections with highly pathogenic avian influenza (HPAI) virus have been reported to the WHO, of which 236 have been fatal (www.who.int, accessed 24-3-2008). The actual number of cases may be much higher as most infected people live in rural areas with poor access to healthcare and appropriate diagnostic tests.

The genetic plasticity of influenza viruses and previous experience with avian virus-derived human influenza pandemics are the major reasons why the current pandemic of influenza A subtype H5N1 in poultry and wild birds is perceived as such a potential threat to human health. In response to this threat, nations worldwide have based their national contingency plans on the stockpiling of anti-influenza drugs and initiated major efforts to develop H5N1 vaccines. However, the effectiveness of these two strategies will depend on the susceptibility of the pandemic strain, should it emerge, to the stockpiled drugs and the protective immune response elicited by vaccines against the current H5N1 strains. The divergence of influenza H5N1 viruses into several clades challenges these efforts.[2] To date, 10 different genetic clades have been distinguished, some of which have a distinct geographical distribution. The most diverse clade, clade 2, can be subdivided into 5 subclades. Human infections have been caused by (sub)clades 1, 2.1, 2.2, 2.3 and 7 [3].

Between 2003 and 2005, influenza H5N1 outbreaks in poultry and humans in Vietnam were caused by clade 1 viruses [3]–[5]. These viruses were typically resistant to amantadine but susceptible to oseltamivir [3], [6], although the emergence of oseltamivir resistant strains in patients during treatment has been reported [7], [8]. Like most other countries, Vietnam has stockpiled oseltamivir for use in the event of a pandemic. Furthermore, Vietnam has developed a prototype reverse genetics-generated human H5N1 vaccine derived from a clade 1 H5N1 influenza isolate (A/Vietnam/1194/2004).

In 2005 Vietnam started nation-wide poultry vaccination programs which may have contributed to the absence of widespread poultry outbreaks and human infections throughout 2006 [9]. However, in 2007, human infections with HPAI H5N1 viruses began to reappear in northern Vietnam coincident with outbreaks in poultry and waterfowl. The situation regarding poultry outbreaks was described recently, but data on the human cases and their strain characterization are still lacking [5]. Here, we report the clinical characteristics and outcome of patients infected with H5N1 viruses emerging in Vietnam in 2007. H5N1 strains isolated from the human cases were genetically characterized and susceptibility to neuraminidase inhibitors and amantadine were assessed.

Methods

Influenza diagnostics

Throat swabs or tracheal aspirates were collected on admission from patients with clinically suspected H5N1 infection in northern Vietnam and sent to the National Institute of Hygiene and Epidemiology (NIHE) for the detection of influenza A H5N1 virus using reverse transcriptase polymerase chain reaction (RT PCR) and viral culture [10]. The national case definition for suspected H5N1 infection is: sudden onset of fever>38°C; difficulty in breathing; infiltrates on the chest X-ray; and a low total leucocyte count in blood. Additional clinical specimens (rectal swabs, blood, pleural fluid), from suspected or confirmed patients that were admitted to the National Hospital of Pediatrics, National Institute of Infectious and Tropical Diseases, and Bach Mai Hospital, all situated in Hanoi, were tested by real time RT PCR and virus isolation at the Oxford University Clinical Research Unit (OUCRU) in Vietnam and at NIHE [11].

For virus isolation, clinical specimens were inoculated onto Madin-Darby Canine Kidney (MDCK) cells in biosafety level 3 laboratories. Virus isolates were identified by RT PCR and hemagglutination inhibition (HAI) with reference antiserum to A/Duck/Hong Kong/820/80 (H5N3). In vitro susceptibility of virus isolates to oseltamivir carboxylate was determined by a chemiluminiscent neuraminidase inhibition assay (NA-Star, Applied Biosystems) and to zanamivir by fluorescent neuraminidase inhibition assay, as described previously [12], [13]. A total of 16 virus isolates were tested by neuraminidase inhibition assay: four available human H5N1 strains from 2007, 11 human clade 1 H5N1 viruses isolated in Vietnam between 2004 and 2005, and one human clade 2.3.4 H5N1 strain isolated in Vietnam in 2005. Specimens and strains were stored at −80°C.

Acute and convalescent sera from the first three patients were tested for the presence of H5-specific antibodies by hemagglutination inhibition assay (HAI) using chicken red blood cells and clade 1 (A/Hanoi 3040/2004) and clade 2.3.4 virus (A/Hanoi 31244/2007) antigens. While it is recognised that horse red blood cells are optimal for detecting human antibody responses to H5N1 viruses, horse red blood cells were not readily available in Vietnam.

Sequencing and phylogenetic analysis

Sequence analysis of the HA gene was performed on six human H5N1 isolates and 11 poultry isolates obtained in 2007. Viral RNA was extracted from virus isolates by use of an RNA extraction kit (QIAamp, Qiagen, Netherlands), according to the manufacturer's protocol. cDNA was synthesized using the A-U12 primer (5′-AGCAAAAGCAGG-3′), which is complementary to the 3′ end of the viral RNA, and reverse transcriptase (SuperScript III; Invitrogen, USA) according to the manufacturer's protocol. The resultant cDNA products were used to amplify the hemagglutinin (HA) gene by a standard PCR method (Proof Start DNA Polymerase; Qiagen, Netherlands) with the following primer pair: H5F: AGC AAA AGC AGG GGT TCA ATC TGT CAA AAT GG and H5R: AGT AGA AAC AAG GGT GTT TTT AAC TAC AAT CTG.

Purified PCR products were sequenced using BigDye Terminator version 3.1 Cycle Sequencing Kit on an ABI 3100 Genetic Analyzer (Applied Biosystems, CA, USA) following the manufacturer's instructions. Haemagglutinin sequences of poultry and human isolates were phylogenetically analyzed together with representative virus sequences available in GenBank, including vaccine candidate strains. Phylogenetic trees of the HA gene segment were created using the maximum likelihood method available in DNASIS-MAX version 02–06 (Hitachi-Japan). Neuraminidase and M2 gene sequencing was performed to assess mutations coding for oseltamivir and amantadine resistance, respectively. The following primers were used for this purpose: NA-534F: TTG CTT GGT CAG CAA GTG C and NA-1149R: TCT GTC CAT CCA TTA GGA TCC for neuraminidase gene and M2F: CTA GTC AGG CCA GGC AAA TG and M2R: ACT GTC GTC AGC ATC CAC AG for M2 gene. Neuraminidase gene sequencing was performed both on human and poultry H5N1 isolates, and M2 sequencing only on human H5N1 isolates.

Results

In 2007, a total of 295 clinical specimens collected from 251 patients in northern Vietnam with suspected H5N1 infection, were tested by RT-PCR at NIHE. Of these, H5N1 infection was confirmed in a total of eight (3.2%) patients: six males and two females (median age 23 y, range: 4–30 y, Table 1). One patient (patient 6) was seven months pregnant. Seven of the patients reported exposure to poultry prior to onset of illness, and five lived in an area with reported poultry outbreaks (Figure 1). Human infections occurred between the start of May 2007 and mid December 2007. The median time: (i) from illness onset to admission was 6 days (range: 4–8), (ii) from admission to discharge or death 5.5 days (range: 1–41), and (iii) from disease onset to death 10 days (range: 7–19). The patients were admitted to four different hospitals in northern Vietnam. No human case was epidemiologically linked with another.

[Figure omitted. See PDF.]

Figure 1. Mapping of poultry and human H5N1 cases in northern Vietnam, 2007.

https://doi.org/10.1371/journal.pone.0003339.g001

[Figure omitted. See PDF.]

Table 1. Clinical features of all eight detected human H5N1 cases in Vietnam, 2007.

https://doi.org/10.1371/journal.pone.0003339.t001

Clinical features

All patients presented with fever, cough and dyspnea. Mean oxygen saturation was 81% (range: 40–93%) at admission. Pleuritic chest pain was reported by all but one patient in whom pleuritic pain could not be assessed as he was a child (patient 8). Diarrhea was reported in three patients. Conjunctivitis was not a clinical feature. Chest X rays showed bilateral pulmonary infiltration in all patients. Median total leucocyte counts and lymphocyte counts were 4,100 cells/mm3 (range: 2,000–28,700) and 750 cells/mm3 (range: 300–1,700), respectively. The median platelet count was 117,000/mm3 (range: 87,000–164,000). Seven patients required mechanical ventilation early after admission. One patient that survived (patient 3) only received supplemental oxygen and did not require mechanical ventilation. Five patients developed ARDS and pneumothoraces, and in three cases pleural effusion was noted.

Treatment and outcome

Oseltamivir was administered to all patients within 3 days of admission, corresponding to 5 to 9 days after onset of illness (median: 8 days). After the first two cases had been diagnosed, the time from admission to oseltamivir treatment was reduced from three days to less than one day due to increased awareness. Despite oseltamivir treatment, the mortality was high: 62,5% (5/8). The median time from admission to death was 2 days (range: 1–13). Patient 4 had a very high leucocyte count of 28,700 cells/mm3 and died within 2 days of admission. Aspergillus fumigatus was cultured from his sputum. Patient 5 developed ventilator associated pneumonia (VAP) with Acinetobacter spp and had undetectable levels of influenza RNA at the time of death, 13 days after admission. All patients received low dose steroids during their admission.

All survivors were admitted in May 2007, but originated from different geographical areas (Figure 1). The fatal cases were all admitted between June and December 2007. Compared to those who died, survivors presented earlier to the hospital after illness onset: median of 5 days versus 6 days (Mann-Whitney U test: P = 0.021) and had better oxygenation parameters at admission: mean breathing rate of 28/min and 42/min (Mann-Whitney U test: P = 0.074).

Virology

Quantitative influenza RT PCR data were available from four patients: highest viral loads were found in specimens originating from trachea or throat (obtained 6 to 11 days after onset of symptoms), with viral loads ranging from 1.2×10e5 to 1.1×10e6 cDNA copies/mL. Viral RNA could be detected in the plasma (obtained 7 to 9 days after disease onset) of three of five patients tested (mean viral load: 5.2×10e3 cDNA copies/mL). All three patients with influenza virus RNA in plasma died. Detectable H5N1 RNA was also found in the pleural fluid from two patients with effusions both of which were positive with viral influenza RNA in plasma. Drug susceptibility testing of four virus isolates showed mean IC50 values for oseltamivir and zanamivir of 3.1 nM (n = 4) and 1.3 nM (n = 3), respectively (Table 2). Viruses isolated from sequential specimens obtained at admission and three days later on therapy from one patient showed stable susceptibilities to oseltamivir (IC50 4.75 and 3.86 nM respectively). The mean oseltamivir IC50 for eleven clade 1 viruses isolated from Vietnamese patients in 2004 and 2005 is 0.4 nM (range 0.04 to 1.1 nM), illustrating an eight-fold reduced susceptibility of clade 2.3.4 H5N1 viruses as compared to clade 1 viruses. We also tested the oseltamivir IC50 from a clade 2.3.4 strain isolated in 2005 (A/Vietnam/HN 30850/2005, see below), which was found to be 2.0 nM.

[Figure omitted. See PDF.]

Table 2. Laboratory data of human H5N1 cases in Vietnam, 2007.

https://doi.org/10.1371/journal.pone.0003339.t002

Sequence and phylogenetic analysis of the hemagglutinin gene revealed that the isolated H5N1 viruses were clade 2.3.4 (Figure 2) [14]. Furthermore, we found one of the last human isolates from 2005 to be clade 2.3.4 as well (Figure 2). A polybasic cleavage site motif was present in the HA gene of all sequenced strains. Compared to A/Anhui/1/05 (the current vaccine candidate for clade 2.3), there were 5 to 10 amino acid differences in the HA protein of A/Vietnam/2007 virus (data not shown), which translates to ∼98% homology. In all human H5N1 isolates, no mutations resulting in amino acid substitutions that confer amantadine resistance were found in the M2 gene (L26F, V27A, A30T, S31N, and G34E). In the neuraminidase gene no H274Y or N294S substitution was found. However, in two poultry isolates the I117V substitution was found, conferring reduced susceptibility to oseltamivir.

[Figure omitted. See PDF.]

Figure 2. Phylogenetic analysis of hemagglutinin gene sequence of Influenza A H5N1 in humans and poultry in Vietnam 2007 and sequences downloaded from genebank.

The numbers to the right of the figure refer to the World Health Organization H5N1 clade designations.

https://doi.org/10.1371/journal.pone.0003339.g002

Discussion

Here we report on human A H5N1 virus clade 2.3.4 infections in northern Vietnam in 2007. During the same period, clade 1 viruses continued to circulate in poultry in southern Vietnam but did not cause any recognized human infections [5]. The co-circulation of multiple sub lineages of influenza H5N1 in poultry in Vietnam has been previously reported and suggested to have been introduced from southern China where clade 2.3.4 was already dominant [5]. Whilst the clinical presentation and case fatality ratio of the eight patients infected with clade 2.3.4 avian influenza were similar to earlier Vietnam H5N1 cases with clade 1 H5N1 viruses, there were important differences in the antiviral drug susceptibility profile.

The clade 2.3.4 H5N1 strains isolated from four patients showed up to eight-fold reductions in susceptibility to oseltamivir, when compared to human H5N1 clade 1 strains. Additionally, we showed that one clade 2.3.4 H5N1 virus isolated from a human in 2005 already had a reduced susceptibility to oseltamivir. These levels of reduced susceptibility to oseltamivir are of uncertain clinical significance, but may require higher dosing of oseltamivir [15]. All patients in this report were treated with either standard or double dose oseltamivir. It was striking that most patients were brought to medical attention at a rather late stage of their illness which resulted in a delayed initiation of oseltamivir treatment. Better access to diagnostics and treatment in rural areas will help in reducing this delay and will likely improve outcome [3].

Importantly, no amantadine resistance-conferring mutations were observed in the clade 2.3.4 viruses isolated from these patients, in contrast to clade 1 viruses, which are invariably amantadine resistant, and clade 2.1 and 2.2 H5N1 viruses show varying rates of resistance to the adamantanes [3], [6], [16]. Susceptibility to amantadine allows the use of this agent in combination therapy. Oseltamivir treatment in combination with amantadine increases survival in a mouse model and has shown to be well tolerated in healthy volunteers [17], [18]. Combination therapy has as an additional advantage that it may prevent the development of resistance [19]. Therefore, amantadine combined with oseltamivir needs to be considered in patients infected with amantadine sensitive strains, as is also recommended by the WHO [18], [20]. Monotherapy with amantadine should be avoided because of the high risk of resistance development during treatment [21]. For the same reason, the use of amantadine should be prohibited in poultry farming because this will lead to the emergence of amantadine resistant strains in the animal sector with implications for the treatment of human infections [22]. However, the implementation of such an empiric treatment policy in Vietnam will be difficult as amantadine is not registered in Vietnam.

The co-circulation in Vietnam of two distinct highly pathogenic H5N1 strains has important implications for both animal and human health. By reassortment, clade 2.3.4 viruses may arise with the internal gene constellation of clade 1 viruses, as has already been observed in an H5N1 virus isolated from a duck in Vietnam [5]. The emergence of a new clade with different antigenic properties and antiviral susceptibilities than previous outbreak strains in Vietnam in 2007, underscores the need for timely surveillance with further characterization of isolated strains. Though the I117V substitution was present in two poultry isolates, no known mutation was found that could explain the reduced susceptibility to oseltamivir in the four tested human H5N1 strains. This finding emphasizes the importance of phenotypic analysis of drug susceptibility. Since poultry outbreaks precede and outnumber human cases, phenotypic analysis of drug susceptibility should also be routinely conducted on poultry isolates. These data will help the human health care sector with treatment considerations accordingly in a timely fashion.

Acknowledgments

We thank the medical and nursing staff of the all the hospitals in northern Vietnam that have taken care of patients diagnosed with influenza H5N1, the laboratory staff of the participating hospitals and NIHE for processing and testing specimens at sometimes unfriendly hours, and the South East Asian Influenza Clinical Research Network for setting up diagnostic and research capacity in Southeast Asia, including Vietnam.

Author Contributions

Conceived and designed the experiments: QML HFLW HDN WT HLKN HLKN TQN TVN LTN AF JF HLKN MdJ PH. Performed the experiments: QML HFLW PVMH CDV TDV BTN HVP TN TN QHD MC MdJ. Analyzed the data: QML HFLW WT PVMH CDV TVN TDV BTN HVP TN AF TN QHD MC MdJ PH. Contributed reagents/materials/analysis tools: QML HFLW HDN HLKN HLKN TQN TVN TNB BGN LTN STL PHP QHD JF HLKN MdJ PH. Wrote the paper: QML HDN WT TQN LTN AF JF MdJ PH.

Citation: Le MTQ, Wertheim HFL, Nguyen HD, Taylor W, Hoang PVM, Vuong CD, et al. (2008) Influenza A H5N1 Clade 2.3.4 Virus with a Different Antiviral Susceptibility Profile Replaced Clade 1 Virus in Humans in Northern Vietnam. PLoS ONE3(10): e3339. https://doi.org/10.1371/journal.pone.0003339

References

1. Peiris JS, de Jong MD, Guan Y (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20: 243–267.JS PeirisMD de JongY. Guan2007Avian influenza virus (H5N1): a threat to human health.Clin Microbiol Rev20243267

2. Smith GJ, Naipospos TS, Nguyen TD, de Jong MD, Vijaykrishna D, et al. (2006) Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology 350: 258–268.GJ SmithTS NaiposposTD NguyenMD de JongD. Vijaykrishna2006Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam.Virology350258268

3. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261–273.AN Abdel-GhafarT. ChotpitayasunondhZ. GaoFG HaydenDH Nguyen2008Update on avian influenza A (H5N1) virus infection in humans.N Engl J Med358261273

4. (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11: 1515–1521.2005Evolution of H5N1 avian influenza viruses in Asia.Emerg Infect Dis1115151521

5. Nguyen TD, Nguyen TV, Vijaykrishna D, Webster RG, Guan Y, et al. (2008) Multiple sublineages of Influenza A virus (H5N1), Vietnam, 2005–2007. Emerg Infect Dis 14: 632–636.TD NguyenTV NguyenD. VijaykrishnaRG WebsterY. Guan2008Multiple sublineages of Influenza A virus (H5N1), Vietnam, 2005–2007.Emerg Infect Dis14632636

6. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, et al. (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73: 228–231.AC HurtP. SelleckN. KomadinaR. ShawL. Brown2007Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.Antiviral Res73228231

7. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.QM LeM. KisoK. SomeyaYT SakaiTH Nguyen2005Avian flu: isolation of drug-resistant H5N1 virus.Nature4371108

8. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667–2672.MD de JongTT TranHK TruongMH VoGJ Smith2005Oseltamivir resistance during treatment of influenza A (H5N1) infection.N Engl J Med35326672672

9. Pfeiffer DU, Minh PQ, Martin V, Epprecht M, Otte MJ (2007) An analysis of the spatial and temporal patterns of highly pathogenic avian influenza occurrence in Vietnam using national surveillance data. Vet J 174: 302–309.DU PfeifferPQ MinhV. MartinM. EpprechtMJ Otte2007An analysis of the spatial and temporal patterns of highly pathogenic avian influenza occurrence in Vietnam using national surveillance data.Vet J174302309

10. Dinh PN, Long HT, Tien NT, Hien NT, Mai le TQ, et al. (2006) Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 12: 1841–1847.PN DinhHT LongNT TienNT HienTQ Mai le2006Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004.Emerg Infect Dis1218411847

11. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, et al. (2005) Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352: 686–691.MD de JongVC BachTQ PhanMH VoTT Tran2005Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma.N Engl J Med352686691

12. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, et al. (2000) Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 280: 291–300.RC BuxtonB. EdwardsRR JuoJC VoytaM. Tisdale2000Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.Anal Biochem280291300

13. Gubareva LV, Webster RG, Hayden FG (2002) Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 53: 47–61.LV GubarevaRG WebsterFG Hayden2002Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.Antiviral Res534761

14. Smith GJ, Fan XH, Wang J, Li KS, Qin K, et al. (2006) Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A 103: 16936–16941.GJ SmithXH FanJ. WangKS LiK. Qin2006Emergence and predominance of an H5N1 influenza variant in China.Proc Natl Acad Sci U S A1031693616941

15. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 13: 1354–1357.JL McKimm-BreschkinPW SelleckTB UsmanMA Johnson2007Reduced sensitivity of influenza A (H5N1) to oseltamivir.Emerg Infect Dis1313541357

16. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193: 1626–1629.CL CheungJM RaynerGJ SmithP. WangTS Naipospos2006Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.J Infect Dis19316261629

17. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363–370.NA IlyushinaE. HoffmannR. SalomonRG WebsterEA Govorkova2007Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.Antivir Ther12363370

18. Morrison D, Roy S, Rayner C, Amer A, Howard D, et al. (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2: e1305.D. MorrisonS. RoyC. RaynerA. AmerD. Howard2007A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination.PLoS ONE2e1305

19. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121–131.NA IlyushinaNV BovinRG WebsterEA Govorkova2006Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.Antiviral Res70121131

20. Clinical management of human infection with avian influenza A (H5N1) virus. Clinical management of human infection with avian influenza A (H5N1) virus.World Health Organization Updated advice 15 august 2007 (http://wwwwhoint/csr/disease/avian_influenza/guidelines/ClinicalManagement07pdf). World Health Organization Updated advice 15 august 2007 (http://wwwwhoint/csr/disease/avian_influenza/guidelines/ClinicalManagement07pdf).

21. Hayden FG, Pavia AT (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 194: Suppl 2S119–126.FG HaydenAT Pavia2006Antiviral management of seasonal and pandemic influenza.J Infect Dis194Suppl 2S119126

22. He G, Qiao J, Dong C, He C, Zhao L, et al. (2008) Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 77: 72–76.G. HeJ. QiaoC. DongC. HeL. Zhao2008Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China.Antiviral Res777276